Literature DB >> 28544258

Incidence and risk factors for non-alcoholic fatty liver disease: A 7-year follow-up study among urban, adult Sri Lankans.

Madunil A Niriella1, Arunasalam Pathmeswaran1, Shamila T De Silva1, Anuradhani Kasturiratna1, Ruwan Perera2, Chamila E Subasinghe2, Kuleesha Kodisinghe2, Chathura Piyaratna2, Vithiya Rishikesawan2, Anuradha S Dassanayaka1, Arjuna P De Silva1, Rajitha Wickramasinghe1, Fumihiko Takeuchi3, Norihiro Kato3, Hithanadura J de Silva1.   

Abstract

BACKGROUND: This study investigated incidence and risk factors for NAFLD among an adult cohort with 7-year follow-up.
METHODS: The study population (age-stratified random sampling, Ragama MOH area) was screened initially in 2007 (aged 35-64 years) and re-evaluated in 2014 (aged 42-71 years). On both occasions assessed by structured interview, anthropometric measurements, liver ultrasound, biochemical and serological tests. NAFLD was diagnosed on ultrasound criteria, safe alcohol consumption and absence of hepatitis B/C markers. Non-NAFLD controls did not have any ultrasound criteria for NAFLD. An updated case-control genetic association study for 10 selected genetic variants and NAFLD was also performed.
RESULTS: Out of 2985 of the original cohort, 2148 (72.0%) attended follow-up (1238 [57.6%] women; mean-age 59.2 [SD-7.6] years) in 2014, when 1320 (61.5%) were deemed NAFLD subjects. Out of 778 who initially did not have NAFLD and were not heavy drinkers throughout follow-up, 338 (43.4%) (221 [65.4%] women, mean-age 57.8 [SD-8.0] years) had developed NAFLD after 7-years (annual incidence-6.2%). Central obesity (OR=3.82 [95%-CI 2.09-6.99]), waist increase >5% (OR=2.46 [95%-CI 1.20-5.05]) overweight (OR=3.26 [95%-CI 1.90-5.60]), weight gain 5%-10% (OR=5.70 [95%-CI 2.61-12.47]), weight gain >10% (OR=16.94 [95%-CI 6.88-41.73]), raised plasma triglycerides (OR=1.96 [95%-CI 1.16-3.29]) and diabetes (OR=2.14 [95%-CI 1.13-4.06]), independently predicted the development of incident NAFLD in multivariate analysis. The updated genetic association study (1362-cases, 392-controls) showed replicated association (P=.045, 1-tailed) with NAFLD at a candidate locus: PNPLA3 (rs738409).
CONCLUSIONS: In this community cohort study, the annual incidence of NAFLD was 6.2%. Incident NAFLD was associated with general and central obesity, raised triglycerides and diabetes, and showed a tendency of association with PNPLA3 gene polymorphisms.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Sri Lanka; fatty liver; incidence; non-alcoholic fatty liver disease; risk factors

Mesh:

Substances:

Year:  2017        PMID: 28544258     DOI: 10.1111/liv.13478

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

1.  Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.

Authors:  Madunil Anuk Niriella; Dileepa Senajith Ediriweera; Anuradhani Kasturiratne; Shamila Thivanshi De Silva; Anuradha Supun Dassanayaka; Arjuna Priyadarshin De Silva; Norihiro Kato; Arunasalam Pathmeswaran; Ananda Rajitha Wickramasinghe; Hithanadura Janaka de Silva
Journal:  PLoS One       Date:  2021-02-03       Impact factor: 3.240

2.  Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals.

Authors:  Ehimen C Aneni; Gul Jana Saeed; Marcio Sommer Bittencourt; Miguel Cainzos-Achirica; Chukwuemeka U Osondu; Matthew Budoff; Edison R Parise; Raul D Santos; Khurram Nasir
Journal:  PLoS One       Date:  2022-04-06       Impact factor: 3.240

3.  PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.

Authors:  Bisma Rauff; Ali Amar; Badr Alzahrani; Shafiq A Chudhary; Bilal Nasir; Saqib Mahmood; Munir Ahmad Bhinder; Muhammad Faheem
Journal:  BMC Gastroenterol       Date:  2022-08-26       Impact factor: 2.847

Review 4.  Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review

Authors:  Fajar Dwi Astarini; Neneng Ratnasari; Widya Wasityastuti
Journal:  Iran Biomed J       Date:  2022-07-01

5.  Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up.

Authors:  Jing Wu; Shumei He; Hongqin Xu; Xiumei Chi; Jie Sun; Xiaomei Wang; Xiuzhu Gao; Ruihong Wu; Mingbai Shao; Heng Zhao; Jing Jia; Chunyan Wang; Junqi Niu
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

Review 6.  Nonalcoholic Fatty Liver Disease: Identifying the Disease Burden in Sri Lanka.

Authors:  Anuradha S Dassanayake
Journal:  Euroasian J Hepatogastroenterol       Date:  2018-05-01

7.  Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study.

Authors:  Zhimin Ma; Chaonan Xu; Xiaoping Kang; Shan Zhang; Haibin Li; Lixin Tao; Deqiang Zheng; Xiuhua Guo; Xinghua Yang
Journal:  J Transl Med       Date:  2020-03-19       Impact factor: 5.531

8.  Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: A prospective, cohort follow-up study.

Authors:  Madunil Anuk Niriella; Anuradhani Kasturiratna; Thulani Beddage; Dileepa Senajith Ediriweera; Shamila Thivanshi De Silva; K Ruwan Perera; Chamila Erandaka Subasinghe; S Kuleesha Kodisinghe; T Chathura Piyaratna; Vithiya Rishikesawan; Anuradha Supun Dassanayaka; Arjuna Priyadarshin De Silva; Arunasalam Pathmeswaran; Ananda Rajitha Wickramasinghe; Norihiro Kato; Hithanadura Janaka de Silva
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

9.  Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Nader Salari; Niloufar Darvishi; Kamran Mansouri; Hooman Ghasemi; Melika Hosseinian-Far; Fateme Darvishi; Masoud Mohammadi
Journal:  BMC Endocr Disord       Date:  2021-06-19       Impact factor: 2.763

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.